|
US4452773A
(en)
|
1982-04-05 |
1984-06-05 |
Canadian Patents And Development Limited |
Magnetic iron-dextran microspheres
|
|
US4690915A
(en)
|
1985-08-08 |
1987-09-01 |
The United States Of America As Represented By The Department Of Health And Human Services |
Adoptive immunotherapy as a treatment modality in humans
|
|
US4795698A
(en)
|
1985-10-04 |
1989-01-03 |
Immunicon Corporation |
Magnetic-polymer particles
|
|
US5219740A
(en)
|
1987-02-13 |
1993-06-15 |
Fred Hutchinson Cancer Research Center |
Retroviral gene transfer into diploid fibroblasts for gene therapy
|
|
ATE114507T1
(de)
|
1988-12-28 |
1994-12-15 |
Stefan Miltenyi |
Verfahren sowie materialien zur hochgraduierten magnetischen abspaltung biologischer materialien.
|
|
US5200084A
(en)
|
1990-09-26 |
1993-04-06 |
Immunicon Corporation |
Apparatus and methods for magnetic separation
|
|
DE4228458A1
(de)
|
1992-08-27 |
1994-06-01 |
Beiersdorf Ag |
Multicistronische Expressionseinheiten und deren Verwendung
|
|
US5827642A
(en)
|
1994-08-31 |
1998-10-27 |
Fred Hutchinson Cancer Research Center |
Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
|
|
DE19608753C1
(de)
|
1996-03-06 |
1997-06-26 |
Medigene Gmbh |
Transduktionssystem und seine Verwendung
|
|
US6451995B1
(en)
|
1996-03-20 |
2002-09-17 |
Sloan-Kettering Institute For Cancer Research |
Single chain FV polynucleotide or peptide constructs of anti-ganglioside GD2 antibodies, cells expressing same and related methods
|
|
WO2000014257A1
(en)
|
1998-09-04 |
2000-03-16 |
Sloan-Kettering Institute For Cancer Research |
Fusion receptors specific for prostate-specific membrane antigen and uses thereof
|
|
AU2472400A
(en)
|
1998-10-20 |
2000-05-08 |
City Of Hope |
CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies
|
|
CA2410510A1
(en)
|
2000-06-02 |
2001-12-13 |
Memorial Sloan-Kettering Cancer Center |
Artificial antigen presenting cells and methods of use thereof
|
|
US7446179B2
(en)
|
2000-11-07 |
2008-11-04 |
City Of Hope |
CD19-specific chimeric T cell receptor
|
|
ES2257461T3
(es)
|
2000-12-21 |
2006-08-01 |
Bristol-Myers Squibb Company |
Inhibidores de tiazolilo de tirosina quinasas de la familia tec.
|
|
US7070995B2
(en)
|
2001-04-11 |
2006-07-04 |
City Of Hope |
CE7-specific redirected immune cells
|
|
US20090257994A1
(en)
|
2001-04-30 |
2009-10-15 |
City Of Hope |
Chimeric immunoreceptor useful in treating human cancers
|
|
US7939059B2
(en)
|
2001-12-10 |
2011-05-10 |
California Institute Of Technology |
Method for the generation of antigen-specific lymphocytes
|
|
US20030170238A1
(en)
|
2002-03-07 |
2003-09-11 |
Gruenberg Micheal L. |
Re-activated T-cells for adoptive immunotherapy
|
|
US7446190B2
(en)
|
2002-05-28 |
2008-11-04 |
Sloan-Kettering Institute For Cancer Research |
Nucleic acids encoding chimeric T cell receptors
|
|
SE0202463D0
(sv)
|
2002-08-14 |
2002-08-14 |
Astrazeneca Ab |
Novel compounds
|
|
SE0202462D0
(sv)
|
2002-08-14 |
2002-08-14 |
Astrazeneca Ab |
Novel use
|
|
SE0202461D0
(sv)
|
2002-08-14 |
2002-08-14 |
Astrazeneca Ab |
Novel compounds
|
|
SE0202429D0
(sv)
|
2002-08-14 |
2002-08-14 |
Astrazeneca Ab |
Novel Compounds
|
|
US20050129671A1
(en)
|
2003-03-11 |
2005-06-16 |
City Of Hope |
Mammalian antigen-presenting T cells and bi-specific T cells
|
|
WO2005026175A1
(en)
|
2003-09-08 |
2005-03-24 |
Aventis Pharmaceuticals Inc. |
Thienopyrazoles
|
|
US20050176792A1
(en)
|
2004-01-14 |
2005-08-11 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Ketone substituted benzimidazole compounds
|
|
WO2005079791A1
(en)
|
2004-02-12 |
2005-09-01 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Thiophene -2- carboxylic acid - (1h - benzimidazol - 2 yl) - amide derivatives and related compounds as inhibitors of the tec kinase itk (interleukin -2- inducible t cell kinase) for the treatment of inflammation, immunological and allergic disorders
|
|
MX2007007330A
(es)
|
2004-12-16 |
2007-10-04 |
Vertex Pharma |
Piridonas de utilidad como inhibidores de quinasas .
|
|
WO2007016977A1
(de)
|
2005-08-05 |
2007-02-15 |
Delica Ag |
Vorrichtung zum extrahieren eines in einer kapsel enthaltenen extraktionsgutes mit einem flüssigen extraktionsmittel
|
|
AU2006285038A1
(en)
|
2005-08-29 |
2007-03-08 |
Vertex Pharmaceuticals Incorporated |
3,5-disubstituted pyrid-2-ones useful as inhibitors of Tec family of non-receptor tyrosine kinases
|
|
WO2007058832A2
(en)
|
2005-11-12 |
2007-05-24 |
Boehringer Ingelheim International Gmbh |
Pyrrolo (2, 3-b) pyridine derivatives useful as tec kinase inhibitors
|
|
WO2007076228A2
(en)
|
2005-12-20 |
2007-07-05 |
Boehringer Ingelheim International Gmbh |
2-(ih-thieno [3,2-c] pyrazol-3yl)-ih-indole derivatives and related compounds as tec kinase inhibitors for the treatment of inflammations and immunological disorders
|
|
US8604031B2
(en)
|
2006-05-18 |
2013-12-10 |
Mannkind Corporation |
Intracellular kinase inhibitors
|
|
EP1900739A1
(en)
|
2006-08-30 |
2008-03-19 |
Cellzome Ag |
Diazolodiazine derivatives as kinase inhibitors
|
|
JP5336375B2
(ja)
|
2006-08-30 |
2013-11-06 |
セルゾーム リミテッド |
キナーゼ阻害剤としてのトリアゾール誘導体
|
|
EP1900727A1
(en)
|
2006-08-30 |
2008-03-19 |
Cellzome Ag |
Aminopyridine derivatives as kinase inhibitors
|
|
EP2529621B1
(en)
|
2006-09-22 |
2016-10-05 |
Pharmacyclics LLC |
Inhibitors of bruton's tyrosine kinase
|
|
US8389282B2
(en)
|
2007-03-30 |
2013-03-05 |
Memorial Sloan-Kettering Cancer Center |
Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes
|
|
JP5600063B2
(ja)
|
2007-10-19 |
2014-10-01 |
セルジーン アビロミクス リサーチ, インコーポレイテッド |
ヘテロアリール化合物およびその使用
|
|
EP2520643B8
(en)
|
2007-12-07 |
2019-11-27 |
Miltenyi Biotec B.V. & Co. KG |
Sample processing systems and methods
|
|
US8479118B2
(en)
|
2007-12-10 |
2013-07-02 |
Microsoft Corporation |
Switching search providers within a browser search box
|
|
US20120164718A1
(en)
|
2008-05-06 |
2012-06-28 |
Innovative Micro Technology |
Removable/disposable apparatus for MEMS particle sorting device
|
|
JP5173594B2
(ja)
|
2008-05-27 |
2013-04-03 |
キヤノン株式会社 |
管理装置、画像形成装置及びそれらの処理方法
|
|
AU2009262068C1
(en)
|
2008-06-27 |
2015-07-02 |
Celgene Car Llc |
Heteroaryl compounds and uses thereof
|
|
US8338439B2
(en)
|
2008-06-27 |
2012-12-25 |
Celgene Avilomics Research, Inc. |
2,4-disubstituted pyrimidines useful as kinase inhibitors
|
|
WO2011017219A1
(en)
|
2009-08-03 |
2011-02-10 |
The Regents Of The University Of California |
Imidazoquinoxalinones and anti-tumor treatment
|
|
JP5956342B2
(ja)
|
2009-11-03 |
2016-07-27 |
シティ・オブ・ホープCity of Hope |
形質導入T細胞選択のためのトランケート上皮増殖因子レセプタ(EGFRt)
|
|
MX380504B
(es)
|
2010-06-03 |
2025-03-12 |
Pharmacyclics Llc |
El uso de inhibidores de la tirosina quinasa de bruton (btk).
|
|
PH12013501201A1
(en)
|
2010-12-09 |
2013-07-29 |
Univ Pennsylvania |
Use of chimeric antigen receptor-modified t cells to treat cancer
|
|
WO2012129514A1
(en)
|
2011-03-23 |
2012-09-27 |
Fred Hutchinson Cancer Research Center |
Method and compositions for cellular immunotherapy
|
|
US8398282B2
(en)
|
2011-05-12 |
2013-03-19 |
Delphi Technologies, Inc. |
Vehicle front lighting assembly and systems having a variable tint electrowetting element
|
|
WO2013071154A1
(en)
|
2011-11-11 |
2013-05-16 |
Fred Hutchinson Cancer Research Center |
Cyclin a1-targeted t-cell immunotherapy for cancer
|
|
EP2814846B1
(en)
|
2012-02-13 |
2020-01-08 |
Seattle Children's Hospital d/b/a Seattle Children's Research Institute |
Bispecific chimeric antigen receptors and therapeutic uses thereof
|
|
WO2013126726A1
(en)
|
2012-02-22 |
2013-08-29 |
The Trustees Of The University Of Pennsylvania |
Double transgenic t cells comprising a car and a tcr and their methods of use
|
|
NZ702108A
(en)
|
2012-05-03 |
2016-09-30 |
Hutchinson Fred Cancer Res |
Enhanced affinity t cell receptors and methods for making the same
|
|
MA37711A1
(fr)
|
2012-06-04 |
2017-05-31 |
Pharmacyclics Inc |
Formes cristallines d'un inhibiteur de tyrosine kinase de bruton
|
|
WO2014004707A1
(en)
|
2012-06-29 |
2014-01-03 |
Principia Biopharma Inc. |
Formulations comprising ibrutinib
|
|
LT2884999T
(lt)
|
2012-08-20 |
2021-04-12 |
Fred Hutchinson Cancer Research Center |
Ląstelinės imunoterapijos būdas ir kompozicijos
|
|
RU2729401C2
(ru)
|
2012-10-02 |
2020-08-06 |
Мемориал Слоан-Кеттеринг Кэнсер Сентер |
Композиции и способы для иммунотерапии
|
|
SG11201503459SA
(en)
|
2012-11-02 |
2015-06-29 |
Pharmacyclics Inc |
Tec family kinase inhibitor adjuvant therapy
|
|
US9649313B2
(en)
|
2012-11-26 |
2017-05-16 |
The University Of North Carolina At Chapel Hill |
Use of ITK inhibitors for the treatment of cancer
|
|
US9260426B2
(en)
|
2012-12-14 |
2016-02-16 |
Arrien Pharmaceuticals Llc |
Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors
|
|
JP5372297B1
(ja)
|
2012-12-20 |
2013-12-18 |
三菱電機株式会社 |
車載装置及びプログラム
|
|
US9422267B2
(en)
|
2012-12-26 |
2016-08-23 |
Medivation Technologies, Inc. |
Fused pyrimidine compounds and use thereof
|
|
AU2014244518A1
(en)
|
2013-03-14 |
2015-09-17 |
Pharmacyclics Llc |
Combinations of Bruton's tyrosine kinase inhibitors and CYP3A4 inhibitors
|
|
US9550760B2
(en)
|
2013-03-15 |
2017-01-24 |
Nantbioscience, Inc. |
Substituted indol-5-ol derivatives and their therapeutic applications
|
|
US20160287592A1
(en)
|
2013-04-08 |
2016-10-06 |
Pharmacyclics Llc |
Ibrutinib combination therapy
|
|
US8957080B2
(en)
|
2013-04-09 |
2015-02-17 |
Principia Biopharma Inc. |
Tyrosine kinase inhibitors
|
|
US9206188B2
(en)
|
2013-04-18 |
2015-12-08 |
Arrien Pharmaceuticals Llc |
Substituted pyrrolo[2,3-b]pyridines as ITK and JAK inhibitors
|
|
CA2913052A1
(en)
|
2013-05-24 |
2014-11-27 |
Board Of Regents, The University Of Texas System |
Chimeric antigen receptor-targeting monoclonal antibodies
|
|
US9108442B2
(en)
|
2013-08-20 |
2015-08-18 |
Ricoh Company, Ltd. |
Image forming apparatus
|
|
CN103694241A
(zh)
|
2013-11-27 |
2014-04-02 |
苏州晶云药物科技有限公司 |
Pci-32765的新晶型a及其制备方法
|
|
NZ759969A
(en)
|
2013-12-20 |
2022-12-23 |
Fred Hutchinson Cancer Center |
Tagged chimeric effector molecules and receptors thereof
|
|
WO2015127261A1
(en)
|
2014-02-21 |
2015-08-27 |
Pharmacyclics, Inc. |
Biomarkers for predicting response of dlbcl to treatment with ibrutinib
|
|
EP3122753A4
(en)
|
2014-03-27 |
2017-11-29 |
Perrigo Api Ltd. |
Ibrutinib solid forms and production process therefor
|
|
WO2015187848A1
(en)
|
2014-06-04 |
2015-12-10 |
Sampath Deepa |
Hdac inhibitor and btk inhibitor combinations
|
|
WO2015192081A1
(en)
|
2014-06-13 |
2015-12-17 |
Byrd, John C. |
Biomarker for predicting response of cll to treatment with a btk inhibitor
|
|
US20170128448A1
(en)
|
2014-07-11 |
2017-05-11 |
Celgene Corporation |
Combination therapy for cancer
|
|
WO2016014859A1
(en)
|
2014-07-25 |
2016-01-28 |
Pharmacyclics Llc |
Bet inhibitor and bruton's tyrosine kinase inhibitor combinations
|
|
US9545407B2
(en)
|
2014-08-07 |
2017-01-17 |
Pharmacyclics Llc |
Formulations of a bruton's tyrosine kinase inhibitor
|
|
MX2017001656A
(es)
|
2014-08-08 |
2017-07-24 |
Pharmacyclics Llc |
Combinaciones de inhibidor de tirosina cinasa de bruton y usos de estas.
|
|
CA2958139A1
(en)
|
2014-08-14 |
2016-02-18 |
Assia Chemical Industries Ltd. |
Solid state forms of ibrutinib
|
|
TWI751102B
(zh)
|
2014-08-28 |
2022-01-01 |
美商奇諾治療有限公司 |
對cd19具專一性之抗體及嵌合抗原受體
|
|
WO2016050422A1
(en)
|
2014-10-01 |
2016-04-07 |
Ratiopharm Gmbh |
Acid addition salt of ibrutinib
|
|
WO2016088074A1
(en)
|
2014-12-03 |
2016-06-09 |
Dr. Reddy’S Laboratories Limited |
Process for the preparation of amorphous ibrutinib
|
|
CA2970043A1
(en)
|
2014-12-23 |
2016-06-30 |
Pharmacyclics Llc |
Btk inhibitor combinations and dosing regimen
|
|
MA41350A
(fr)
|
2015-01-14 |
2017-11-21 |
Janssen Pharmaceutica Nv |
Synthèse d'un inhibiteur de la tyrosine kinase de bruton
|
|
IL315294A
(en)
|
2015-03-03 |
2024-10-01 |
Pharmacyclics Llc |
Pharmaceutical formulations of proton tyrosine kinase inhibitor
|
|
EP3265092A4
(en)
|
2015-03-03 |
2018-07-18 |
Dr. Reddy's Laboratories Ltd. |
Polymorphs of ibrutinib
|
|
WO2016151438A1
(en)
|
2015-03-20 |
2016-09-29 |
Sun Pharmaceutical Industries Limited |
A process for the preparation of ibrutinib
|
|
WO2016156127A1
(en)
|
2015-04-02 |
2016-10-06 |
Ratiopharm Gmbh |
Co-crystals of ibrutinib with carboxylic acids
|
|
CA2996177A1
(en)
|
2015-08-31 |
2017-03-09 |
Pharmacyclics Llc |
Btk inhibitor combinations for treating multiple myeloma
|
|
ITUB20155616A1
(it)
|
2015-11-16 |
2017-05-16 |
Laboratorio Chimico Int S P A |
Procedimento per la preparazione della forma amorfa dell?ibrutinib e nuova forma cristallina.
|
|
WO2017134684A2
(en)
|
2016-02-01 |
2017-08-10 |
Natco Pharma Limited |
An improved process for the preparation of ibrutinib
|
|
US10435409B2
(en)
|
2016-02-04 |
2019-10-08 |
Shilpa Medicare Limited |
Process for the preparation of ibrutinib
|
|
GB2558514A
(en)
|
2016-02-09 |
2018-07-18 |
Azad Pharmaceutical Ingredients Ag |
Process for the synthesis of stable amorphous ibrutinib
|
|
WO2017214207A2
(en)
*
|
2016-06-06 |
2017-12-14 |
Juno Therapeutics, Inc. |
Methods for the treatment of b cell malignancies using adoptive cell therapy
|
|
KR20230047507A
(ko)
|
2016-06-27 |
2023-04-07 |
더 리젠츠 오브 더 유니버시티 오브 캘리포니아 |
암 치료 조합
|